Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Stock price

Equities

600671

CNE000000BF3

Pharmaceuticals

End-of-day quote Shanghai S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
8.96 CNY -0.99% Intraday chart for Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd +2.40% -23.16%
Sales 2021 147M 20.37M Sales 2022 109M 15.08M Capitalization 1.16B 160M
Net income 2021 -29M -4.02M Net income 2022 -67M -9.28M EV / Sales 2021 8.06 x
Net Debt 2021 91.41M 12.66M Net Debt 2022 73.65M 10.2M EV / Sales 2022 11.3 x
P/E ratio 2021
-37.4 x
P/E ratio 2022
-17.3 x
Employees 371
Yield 2021 *
-
Yield 2022
-
Free-Float 38.72%
More Fundamentals * Assessed data
Dynamic Chart
Qingdao Yuanjia Medical Treatment Technology proposal of Adding Sheng Xiaofan to the Company's Eleventh Board of Directors to Hangzhou TianMuShan Pharmaceutical Enterprise was approved. CI
On October 19, 2023 Qingdao Yuanjia Medical Treatment Technology propose of Adding Sheng Xiaofan to the Company's Eleventh Board of Directors to Hangzhou TianMuShan Pharmaceutical Enterprise. CI
TianMuShan Pharma Elects Chairman MT
Qingdao Yuanjia Medical Treatment Technology Co., Ltd. completed the acquisition of 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. CI
Qingdao Huilong Huaze Investment Co., Ltd. completed the acquisition of 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
TianMuShan Pharmaceutical CFO Steps Down MT
Qingdao Huilong Huaze Investment Co., Ltd. agreed to acquire 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY 90 million. CI
Qingdao Yuanjia Medical Treatment Technology Co., Ltd. agreed to acquire 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY140 million. CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd announced that it expects to receive CNY 278.385575 million in funding from Qingdao Huilong Huaze Investment Co., Ltd. CI
Yongxin Huarui Proposes Board and Supervisory Board Nominations for Hangzhou Tianmushan's Board CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Auditor Raises 'Going Concern' Doubt CI
More news
1 day-0.99%
1 week+2.40%
Current month-1.10%
1 month-0.55%
3 months-26.01%
6 months-7.44%
Current year-23.16%
More quotes
1 week
8.60
Extreme 8.6
9.14
1 month
8.45
Extreme 8.45
9.17
Current year
8.31
Extreme 8.31
11.81
1 year
7.17
Extreme 7.17
12.41
3 years
7.17
Extreme 7.17
12.41
5 years
5.97
Extreme 5.97
27.92
10 years
5.97
Extreme 5.97
39.71
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 23-09-26
Director of Finance/CFO 46 23-09-26
Director/Board Member 37 21-05-25
Members of the board TitleAgeSince
Director/Board Member 55 91-12-31
Director/Board Member 37 21-05-25
Director of Finance/CFO 46 23-09-26
More insiders
Date Price Change Volume
24-03-28 8.96 -0.99% 531,100
24-03-27 9.05 +4.02% 1,310,500
24-03-26 8.7 +0.93% 285,101
24-03-25 8.62 -0.58% 430,801
24-03-22 8.67 -0.91% 727,800

End-of-day quote Shanghai S.E., March 27, 2024

More quotes
Hangzhou TianMuShan Pharmaceutical Enterprise Co., Ltd is a China based company principally engaged in the research and development, production and sales of pharmaceuticals and related health products. The Company is mainly engaged in the manufacture of chemical drug substances, processing of Chinese herbal pieces as well as the manufacture of traditional Chinese medicine preparation and Western medicine. The Company's main products are bright eye drops, FufangXianzhuliYe, amoxicillin and clavulanate potassium tablets, Hechedazao Jiaonang, Liu Wei Di Huang oral liquid, menthol, and peppermint oil. The Company mainly operates its business in the domestic market.
More about the company
  1. Stock
  2. Equities
  3. Stock Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd - Shanghai S.E.